Alejandro Barrera
Overview
Explore the profile of Alejandro Barrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rohm D, Black J, McCutcheon S, Barrera A, Berry S, Morone D, et al.
Cell Genom
. 2025 Feb;
5(2):100770.
PMID: 39947136
Epigenome editing with DNA-targeting technologies such as CRISPR-dCas9 can be used to dissect gene regulatory mechanisms and potentially treat associated disorders. For example, Prader-Willi syndrome (PWS) results from loss of...
2.
Liu S, Hamilton M, Cowart T, Barrera A, Bounds L, Nelson A, et al.
Cell Genom
. 2025 Feb;
5(2):100766.
PMID: 39914388
Single-cell RNA sequencing CRISPR (perturb-seq) screens enable high-throughput investigation of the genome, allowing for characterization of thousands of genomic perturbations on gene expression. Ambient gRNAs, which are contaminating gRNAs, are...
3.
Beaman M, Yin W, Smith A, Sears P, Leigh M, Ferkol T, et al.
Am J Med Genet A
. 2024 Oct;
197(2):e63880.
PMID: 39364610
Variation in the non-coding genome represents an understudied mechanism of disease and it remains challenging to predict if single nucleotide variants, small insertions and deletions, or structural variants in non-coding...
4.
Pacheco F, Barrera A, Ciro Y, Polo-Ceron D, Salamanca C, Onate-Garzon J
Pharmaceutics
. 2024 Sep;
16(9).
PMID: 39339153
The natural evolution of microorganisms, as well as the inappropriate use of medicines, have accelerated the problem of drug resistance to many of the antibiotics employed today. Colistin, a lipopeptide...
5.
Gallardo C, Barrera A, Sepulveda J, Illanes F, Concha X
Colorectal Dis
. 2024 Sep;
26(11):2009-2010.
PMID: 39295158
No abstract available.
6.
Liu S, Hamilton M, Cowart T, Barrera A, Bounds L, Nelson A, et al.
bioRxiv
. 2024 Sep;
PMID: 39282389
Recent technological developments in single-cell RNA-seq CRISPR screens enable high-throughput investigation of the genome. Through transduction of a gRNA library to a cell population followed by transcriptomic profiling by scRNA-seq,...
7.
Nussbaum D, Martz C, Waters A, Barrera A, Liu A, Rutter J, et al.
NPJ Precis Oncol
. 2024 May;
8(1):124.
PMID: 38822082
Acquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have...
8.
Mu W, Luo T, Barrera A, Bounds L, Klann T, Ter Weele M, et al.
bioRxiv
. 2024 Apr;
PMID: 38659894
CRISPR epigenomic editing technologies enable functional interrogation of non-coding elements. However, current computational methods for guide RNA (gRNA) design do not effectively predict the power potential, molecular and cellular impact...
9.
Yao D, Tycko J, Oh J, Bounds L, Gosai S, Lataniotis L, et al.
Nat Methods
. 2024 Mar;
21(4):723-734.
PMID: 38504114
The ENCODE Consortium's efforts to annotate noncoding cis-regulatory elements (CREs) have advanced our understanding of gene regulatory landscapes. Pooled, noncoding CRISPR screens offer a systematic approach to investigate cis-regulatory mechanisms....
10.
Rohm D, Black J, McCutcheon S, Barrera A, Morone D, Nuttle X, et al.
bioRxiv
. 2024 Mar;
PMID: 38496583
Epigenome editing with DNA-targeting technologies such as CRISPR-dCas9 can be used to dissect gene regulatory mechanisms and potentially treat associated disorders. For example, Prader-Willi Syndrome (PWS) is caused by loss...